🇺🇸 FDA
Patent

US 11510887

Sobetirome in the treatment of myelination diseases

granted A61KA61K31/192A61K9/0053

Quick answer

US patent 11510887 (Sobetirome in the treatment of myelination diseases) held by United States Government as represented by the Department of Veterans Affairs expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/192, A61K9/0053, A61K9/0095, A61P